Fig. 4.

HexaBody-CD38 modulates CD38 enzyme activity. The (a) cyclase and (b) hydrolase activity of CD38 expressed on Daudi cells in vitro after incubation with IgG1-CD38-028, HexaBody-CD38, daratumumab, or isatuximab at a concentration of 10 μg/mL. Enzyme activity is expressed as % of the no antibody control (dotted line). Results and the median from three independent experiments are shown. Statistical significance of differences was evaluated using a Friedman test with uncorrected Dunn's post hoc test.